T cell responses to SARS-CoV-2
A large body of evidence generated in the last two and a half years addresses the roles of T
cells in SARS-CoV-2 infection and following vaccination. Infection or vaccination induces …
cells in SARS-CoV-2 infection and following vaccination. Infection or vaccination induces …
[HTML][HTML] Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses
Viruses that replicate in the human respiratory mucosa without infecting systemically,
including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other" …
including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other" …
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …
distinct spike mutations resulting in escape from antibodies induced by previous infection or …
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
highlighted the need for vaccines that not only prevent disease but also prevent …
highlighted the need for vaccines that not only prevent disease but also prevent …
Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination
An inhalable platform for messenger RNA (mRNA) therapeutics would enable minimally
invasive and lung-targeted delivery for a host of pulmonary diseases. Development of lung …
invasive and lung-targeted delivery for a host of pulmonary diseases. Development of lung …
Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
Emergence of SARS-CoV-2 variants of concern (VOCs), including the highly transmissible
Omicron and Delta strains, has posed constant challenges to the current COVID-19 vaccines …
Omicron and Delta strains, has posed constant challenges to the current COVID-19 vaccines …
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic
Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, multiple severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increasing ability to …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increasing ability to …
SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity
SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+
and CD4+ T cells of broad specificity | Journal of Experimental Medicine | Rockefeller …
and CD4+ T cells of broad specificity | Journal of Experimental Medicine | Rockefeller …
[HTML][HTML] SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
F Liew, S Talwar, A Cross, BJ Willett, S Scott… - …, 2023 - thelancet.com
Background Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving
limited insights into mucosal defences that prevent viral replication and onward …
limited insights into mucosal defences that prevent viral replication and onward …
Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ T cell responses post SARS-CoV-2 infection
T cells are a critical component of the response to SARS-CoV-2, but their kinetics after
infection and vaccination are insufficiently understood. Using" spheromer" peptide-MHC …
infection and vaccination are insufficiently understood. Using" spheromer" peptide-MHC …